Sharon Larkin
Known title: DirectorCIK: 0001898172
Associated companies
Transaction History
| SENS | ▲ Buy | Grant | 9,852 | $0 | 5/20/2026 | View on chart |
| SENS | ▲ Buy | Grant | 111,386 | $0 | 5/23/2025 | View on chart |
| SENS | ▲ Buy | Grant | 236,344 | $0 | 5/22/2024 | View on chart |
| SENS | ▼ Sell | Open Market | 30,889 | $19K | 9/7/2023 | View on chart |
| SENS | ▲ Buy | Grant | 147,948 | $0 | 5/17/2023 | View on chart |
| SENS | ▲ Buy | Grant | 99,557 | $0 | 5/26/2022 | View on chart |
| SENS | ▲ Buy | Grant | 3,745 | $7K | 4/1/2022 | View on chart |
| SENS | ▲ Buy | Grant | 72,115 | $0 | 12/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.